Who We Are: Driven to Transform Healthcare
We are a global, science-led, patient-focused pharmaceutical business. At AstraZeneca, We are committed to excellence in the research, development and commercialisation of prescription medicines.
We deliver a diversified portfolio of medicines across primary care, specialty care and rare diseases through our broad-based global network. Through our work in BioPharmaceuticals, we want to transform healthcare, change the lives of billions of people.
Our BioPharmaceuticals R&D and Business Unit are unified in our approach to deliver life-changing medicines for people living with the most common chronic diseases. Our ambition is to stop the progress of these often degenerative, debilitating and life-threatening conditions.
Our commitment to advancing cardiovascular, renal and metabolic treatment
Our ambition is to enhance care to improve outcomes for the millions of people who are living with the complexities of CVRM diseases, to intervene early to protect vital organs, slow or stop disease progression, and one day even cure these often debilitating, progressive and life-threatening conditions.
Our approach focuses on investing in innovative small molecules, drug combinations, nucleotide-based treatments, and advanced biologics. We are pioneering new approaches to clinical development to deliver the next wave of life-changing medicines. By 2030, we aim to be leading the world in CVRM therapies, helping to change the course and reach of medical practice. Our focus areas:
- Cardiovascular: Cardiovascular disease is the leading cause of death worldwide.
At AstraZeneca, we are advancing innovative science to reduce risk, prevent events, and improve outcomes for people living with cardiovascular disease.
- Heart failure: Heart failure is a condition that worsens over time and affects about 64 million people worldwide. That’s why our scientists are dedicated to uncovering the underlying disease biology of heart failure to identify novel disease drivers.
- Renal: Make the Change for Kidney Health is funded by AstraZeneca and co-created with the Global Patient Alliance for Kidney Health. We aim to bring the best possible outcomes for patients, healthcare systems, caregivers, the economy and the planet.
- Metabolism: At AstraZeneca, our mission is to advance research into the next generation of targeted weight management solutions to deliver not only effective weight loss but also durable long-term weight management solutions for people living with obesity and overweight.
Where Science, Innovation, and People Advance CVRM Care
- Our R&D approach: We are investing in a portfolio of next-generation therapeutics and combination medicines which will address multiple risk factors and tackle the underlying drivers of disease across cardiorenal and cardiometabolic diseases to improve health outcomes.
- Our pipeline for CVRM: With more than 25 therapies and therapy combinations in our early-to-late stage pipeline, we seek to bring real science and development to combatting life-threatening conditions.
- Our people: Our team of over 1,000 employees are accomplished and experienced scientists, researchers, clinicians, and healthcare and commercial professionals dedicated to advancing novel science and driving practice change to benefit patients with CVRM diseases.
- Collaboration in CVRM care: We are proud to be working with healthcare professionals, patients, governments and policy makers to improve access to healthcare, and remove barriers to diagnosis and optimal treatment.
Apply Now
- Regional Liaison Director – ATTR (WEST) R-249378 Medical Liaison Wilmington, Delaware
- MSL – ATTR/Cardiovascular - San Francisco, CA R-243698 Medical Liaison Wilmington, Delaware
- MSL – ATTR/Cardiovascular - Minneapolis, MN R-243697 Medical Liaison Wilmington, Delaware
- MSL – ATTR/Cardiovascular - Baltimore, MD R-243695 Medical Liaison Wilmington, Delaware
